Industry News

• Hanger Orthopedic Group reports fourth quarter 2011 results  Hanger Orthopedic announced net sales of $248.1 million for the quarter ended December 31, 2011, an increase of $21.6 million, or 9.5%, from $226.5 million for the fourth quarter of 2010. Diluted EPS were $0.52 for the fourth quarter of 2011 versus $0.02 in the same period in 2010.
  February 08, 2012  
• Neurocrine Biosciences reports fourth quarter and year end 2011 results  Neurocrine reported net income of $37.6 million for the year ended December 31, 2011 versus a net loss of $8.0 million for 2010. Revenues for the year ended December 31, 2011 were $77.4 million, compared with $33.5 million for 2010.
  February 08, 2012  
• Exelixis announces fourth quarter and full year 2011 financial results  Exelixis reported net income of $46.3 million for the fourth quarter ended December 31, 2011 versus a net loss of ($17.9) million for the comparable period in 2010. Revenues for the fourth quarter ended December 31, 2011 were $93.3 million versus $40.8 million for the comparable 2010 period.
  February 08, 2012  
• Stereotaxis announces European adoption milestone and Health Canada  Stereotaxis announced that its Vdrive(TM) Robotic Navigation System, which provides physicians the ability to remotely manipulate traditionally non-robotic catheters, is growing in popularity and is expected to surpass 500 clinical procedures in Europe in February.
  February 08, 2012  
• NIH study links high levels of cadmium, lead in blood to pregnancy delay  Higher blood levels of cadmium in females, and higher blood levels of lead in males, delayed pregnancy in couples trying to become pregnant, according to a study by researchers at the NIH and other academic research institutions.
  February 08, 2012  
• Array BioPharma announces proposed public offering of common stock  Array BioPharma announced that it is offering to sell shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Jefferies & Company and Leerink Swann are acting as joint book-running managers of the proposed offering.
  February 08, 2012  
• Thomas E. Shenk to retire from Merck's board of directors  Merck announced that Thomas E. Shenk, Ph.D., has decided to retire from its board of directors. Dr. Shenk is leaving the board to focus on the new company he is forming to commercialize discoveries made in his Princeton University laboratory in the area of antiviral therapeutics.
  February 08, 2012  
• CDC study finds levels of trans-fatty acids in blood of U.S. white adults has decreased   Blood levels of trans–fatty acids in white adults in the U.S. population decreased by 58 percent from 2000 to 2009 according to a CDC study published in the Journal of the American Medical Association. This is the first time CDC researchers have been able to measure trans fats in human blood.
  February 08, 2012  
• MRF announces first biopharmaceutical partnership with ENDECE Neural, LLC  The Myelin Repair Foundation and ENDECE Neural have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis patients through pre-­‐clinical studies and into Phase I clinical studies.
  February 08, 2012  
• Clostridum difficile-associated diarrhea can be associated with stomach acid drugs  FDA reported that the use of stomach acid drugs known as proton pump inhibitors may be associated with an increased risk of Clostridium difficile–associated diarrhea. The FDA is working with manufacturers to include information about the increased risk of CDAD with use of PPIs in the drug labels.
  February 08, 2012  

   (next 10 articles)